Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.
Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.
On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.
After many years of research, Merck now have a once-daily formulation of raltegravir -- though it requires two tablets with a higher milligram dose.
The ONCEMRK study compared a new once-a-day dosing of raltegravir to the current twice-a-day dosing schedule. This simplification could help individuals improve adherence to their regimens which may result in better suppression of HIV over time.
Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.
Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...